TRAW Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -14868.42% compared to Traws Pharma's net margin of -49.65%. Traws Pharma's return on equity of -124.39% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Traws Pharma has a consensus price target of --, signalling upside risk potential of 302.69%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.43%. Given that Traws Pharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe Traws Pharma is more attractive than NovaBay Pharmaceuticals.

Traws Pharma has a beta of 1.588, which suggesting that the stock is 58.788% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Traws Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Traws Pharma quarterly revenues are $57K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Traws Pharma's net income of -$8.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Traws Pharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma is 10.66x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -14868.42% compared to Traws Pharma's net margin of --. Traws Pharma's return on equity of -124.39% beat Oragenics's return on equity of --.

Traws Pharma has a consensus price target of --, signalling upside risk potential of 302.69%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 457.73%. Given that Oragenics has higher upside potential than Traws Pharma, analysts believe Oragenics is more attractive than Traws Pharma.

Traws Pharma has a beta of 1.588, which suggesting that the stock is 58.788% more volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Traws Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Traws Pharma quarterly revenues are $57K, which are larger than Oragenics quarterly revenues of --. Traws Pharma's net income of -$8.5M is lower than Oragenics's net income of -$3.3M. Notably, Traws Pharma's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma is 10.66x versus 1.12x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -14868.42% compared to Traws Pharma's net margin of --. Traws Pharma's return on equity of -124.39% beat Palatin Technologies's return on equity of --.

Traws Pharma has a consensus price target of --, signalling upside risk potential of 302.69%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 4017.65%. Given that Palatin Technologies has higher upside potential than Traws Pharma, analysts believe Palatin Technologies is more attractive than Traws Pharma.

Traws Pharma has a beta of 1.588, which suggesting that the stock is 58.788% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Traws Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Traws Pharma quarterly revenues are $57K, which are larger than Palatin Technologies quarterly revenues of --. Traws Pharma's net income of -$8.5M is higher than Palatin Technologies's net income of --. Notably, Traws Pharma's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma is 10.66x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -14868.42% compared to Traws Pharma's net margin of --. Traws Pharma's return on equity of -124.39% beat Theriva Biologics's return on equity of --.

Traws Pharma has a consensus price target of --, signalling upside risk potential of 302.69%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 341.18%. Given that Theriva Biologics has higher upside potential than Traws Pharma, analysts believe Theriva Biologics is more attractive than Traws Pharma.

Traws Pharma has a beta of 1.588, which suggesting that the stock is 58.788% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Traws Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Traws Pharma pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Traws Pharma quarterly revenues are $57K, which are larger than Theriva Biologics quarterly revenues of --. Traws Pharma's net income of -$8.5M is lower than Theriva Biologics's net income of -$4.4M. Notably, Traws Pharma's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Traws Pharma is 10.66x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.